Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial-Reference-Cited by-同舟云学术

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Published:2022-10 Issue:10358 Volume:400 Page:1117-1129
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Livingstone Elisabeth,Zimmer Lisa,Hassel Jessica C,Fluck Michael,Eigentler Thomas K,Loquai Carmen,Haferkamp Sebastian,Gutzmer Ralf,Meier Friedegund,Mohr Peter,Hauschild Axel,Schilling Bastian,Menzer Christian,Kiecker Felix,Dippel Edgar,Roesch Alexander,Ziemer Mirjana,Conrad Beate,Körner Silvia,Windemuth-Kieselbach Christine,Schwarz Leonora,Garbe Claus,Becker Jürgen C,Schadendorf Dirk,Livingstone Elisabeth,Zimmer Lisa,Hassel Jessica C,Fluck Michael,Eigentler Thomas K,Loquai Carmen,Haferkamp Sebastian,Gutzmer Ralf,Meier Friedegund,Mohr Peter,Hauschild Axel,Schilling Bastian,Menzer Christian,Kiecker Felix,Dippel Edgar,Roesch Alexander,Ziemer Mirjana,Conrad Beate,Körner Silvia,Simon Jan-Christoph,Herbst Rudolf A,Berking Carola,Utikal Jochen,Sell Sabine,Martens Uwe M,Terheyden Patrick,Stadler Rudolf,Windemuth-Kieselbach Christine,Schwarz Leonora,Garbe Claus,Becker Jürgen C,Schadendorf Dirk

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial;Eggermont;Lancet Oncol,2015

2. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017

3. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018

4. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

5. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial;Eggermont;Eur J Cancer,2019

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma;Hematology/Oncology Clinics of North America;2024-10

3. Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity;Immunotherapy;2024-09-11

4. The Role of Surgery for Stage IV Melanoma;Advances in Surgery;2024-09

5. Research Highlights;Transplantation;2024-08-28